POLATUZUMAB-VEDOTIN+BENDAMUSTIN+RITUXIMAB AS A SALVAGE AND BRIDGING THERAPY IN RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA-CASE PRESENTATION AND LITERATURE OVERVIEW

Ivan Z Petković; Marija Elez; Aleksandar Popovic; Slavica Stojnev; Irena Conic; Miljana Dzunic; Dane Krtinic

doi:10.5937/afmnai42-52138

Ivan Z Petković Klinika za onkologiju, Univerzitetski Klinički Centar Niš https://orcid.org/0000-0002-9110-4117
Asist dr
dr
Slavica Stojnev
doc dr sc med
dr sc med
doc dr sc med

DOI: https://doi.org/10.5937/afmnai42-52138

Keywords: polatuzumab-vedotine, bridging, R/R DLBCL

Abstract

Introduction. Although diffuse large B-cell lymphoma (DLBCL) represents a paradigm of highly curative disease with a complete remission (CR) rate of ≈ 60%–70% in an upfront setting the remaining 30%–40% of patients present a relapse/refractory setting. These population are highly critical and amended for salvage treatment approach. Novel approaches and agents can overcome a problem in 20%–25%. Regarding this problem, polatuzumab vedotine represents one of the options. The use of this agent as a bridging to further consolidation has been introduced from the real world experience with encouraging results.

Case report. We present a 54-year-old male patient diagnosed with primary gastric R/R DLBCL who had been successfully treated by the introduction of antibody drug conjugate polatuzumab vedotine. The patient has been further consolidate with autologous graft.

Conclusion. Given the lack of availability of cellular therapies in developing countries antibody-drug conjugate may be a plausible approach.

Author Biography

Ivan Z Petković, Klinika za onkologiju, Univerzitetski Klinički Centar Niš

Odsek za maligne hemopatije, melanom, sarkome mekih tkiva i tumore nepoznatog primarnog ishodišta i intenzivne nege hemato-onkološkog tipa

Klinika za onkologiju Klinički Centar Niš

Doc.dr sc. med. specijalista interne medicine, subspecijalista onkolog i hematoonkolog

References

1. NCCN. B–cell lymphomas (Version 2.2023).
2. Crump M, Neelapu SS, Faroq U, et al. Outcome in refractory diffuse large B–cell lymphoma: results from the international SCHOLAR-1 study. Blood 2017; 130 (16): 1800-8.
3. Petković I. Current trends in the treatment of primary mediastinal large B-cell lymphoma - an overview. Contemp Oncol (Pozn). 2015;19(6):428-35.
4. Gisselbrect C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 2010;28(27):4184-90.
5. Locke FL, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N Engl J Med 2022;386(7):640-54.
6. Varma G, Goldstein J, Advani RH. Novel agents in relapsed/refractory diffuse large B-cell lymphoma. Hematol Oncol 2023;41(suppl 1): 92-106.
7. Liebers N, Duell J, Fitzgerald D, et al. Polatuzumab vedotin as a salvage and bridging treatment in relapsed and refractory large B-cell lymphomas. Blood Adv 2021;5(13):2707-16.
8. Sehn LH, Herrera AF, Flowers CR, et al. Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol 2020;38(2):155-6.
9. Palanca-Wessels MC, Czuczman M, Salles G, et al. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study. Lancet Oncol. 2015; 16(6): 704-715.
10. Morschhauser F, Flinn IW, Advani R, et al. Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS). Lancet Haematol. 2019; 6(5): e254-e265.
11. Phillips T, Brunvand M, Chen A, et al. Polatuzumab vedotin combined with obinutuzumab for patients with relapsed or refractory non-Hodgkin lymphoma: preliminary safety and clinical activity of a phase Ib/II study. Blood. 2016; 128(22):622.
12. Smith SD, Lopedote P, Samara Y, et al. Polatuzumab vedotin for relapsed/refractory aggressive B-cell lymphoma: a multicenter post-marketing analysis. Clin Lymphoma, Myeloma Leukemia. 2021; 21(3): 170-175.
13. Segman Y, Ribakovsky E, Avigdor A, et al. Outcome of relapsed/refractory diffuse large B-cell lymphoma patients treated with polatuzumab vedotin-based therapy: real-life experience. Leukemia & Lymphoma. 2021/01/02 2021; 62(1): 118-124.
14. Liebers N, Duell J, Fitzgerald D, et al. Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas. Blood Advances. 2021; 5(13): 2707-2716.
15. Northend M, Wilson W, Osborne W, et al. Results of a United Kingdom real-world study of polatuzumab vedotin, bendamustine, and rituximab for relapsed/refractory DLBCL. Blood Advances. 2022; 6(9): 2920-2926.
16. Vodicka P, Benesova K, Janikova A, et al. Polatuzumab vedotin plus bendamustine and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma in the real world. Eur J Haematol. 2022; 109(2):165.
17. Dimou M, Papageorgiou SG, Stavroyianni N, et al. Real-life experience with the combination of polatuzumab vedotin, rituximab, and bendamustine in aggressive B-cell lymphomas. Hematol Oncol. 2021; 39(3): 336-348.